US Pharma MarketingThe post Sensorion secures approval for HearConnex Phase I/II study in France appeared first on Clinical Trials Arena.
Sensorion secures approval for HearConnex Phase I/II study in France
Sensorion has received authorisation from the French ANSM for its clinical trial application to begin HearConnex, a Phase I/II study assessing its investigational gene therapy SENS-601 for hearing loss treatment related to GJB2 gene mutations. SENS-601 is Sensorion’s lead gene therapy candidate for hearing loss. Credit: R Photography Background / Shutterstock.com. Sensorion has received authorisation from the French National Agency for Medicines and Health Products Safety (ANSM) for its clinical trial application to begin HearConnex, a Phase I/II study assessing its investigational gene therapy SENS-601 for hearing loss treatment related to gap junction beta-2 (GJB2) gene mutations. LOA and PTSR…
Sensorion has received authorisation from the French ANSM for its clinical trial application to begin HearConnex, a Phase I/II study assessing its investigational gene therapy SENS-601 for hearing loss treatment related to GJB2 gene mutations.
Source: Clinical Trials Arena